Ranitidine Sedico

**Ranitidine** is a drug from the group of histamine h2 receptor blockers. Produced under the brand name "Ranitgen".

The active substance is methionylsuccinyl hydrochloride, which is considered chemically related to the acid of the same name. In addition, the active substance is in the form of an anhydride. The chemical compound is a white fine powder with a grayish tint, poorly soluble in water, so the finished suspension cannot be stored in a closed container for more than three hours in the sun. The medication is dispensed in tablet form, coated with a film coating. The drug contains several inert ingredients that do not have any pharmacological effect on the patient's body. The medicine is produced in different colors - from light pink to yellow-brown.

The drug is sold in packs made of thick cardboard. Usually the package contains 60 or 120 tablets. There are also blisters containing 25 or 50 pieces. tablets. The expiration date of the medicine can be determined by the code on the plastic container. The drug is stored in a dark, dry, odour-free place. Since the medicine is not highly stable, during long-term storage the dose must be selected individually. The temperature should be 18-25 degrees. After 48 months of storage, the properties are considered lost: a mixture with a shelf life of 1.5 or more years cannot be used for 1 year; from 1 to 2 years – 1 tablet from the package.

Ranitidine is a histamine type 2 receptor blocker. It is used to reduce gastric secretions and to prevent gastroesophageal reflux. It is taken orally. Ranitidine is widely used as a treatment for acid reflux in adults, acute and chronic gastritis. It can also be taken to prevent peptic ulcers and stomach cancer. It is prescribed after the procedure of removing the gallbladder, kidneys and stomach, as well as for the treatment of Solinger-Ellison syndrome. The main contraindications to the use of ranitidine include liver dysfunction, hypersensitivity to the drug, paralysis of the gastrointestinal tract muscles, which is caused by a congenital defect in the gene responsible for this disease, myotonia, cerebral palsy and other conditions associated with muscle weakness, severe renal and liver failure and individual intolerance. When taking ranitidine, side effects may occur, such as headache, insomnia, arrhythmia, tremor, fatigue, nausea and others. The risk of complications increases with the use of large doses of the drug, prolonged use, and repeated use. An overdose of the drug is characterized by convulsions, bradycardia or tachycardia, changes in the functioning of the kidneys, platelets and hematopoietic system. Depending on the nature and severity of the complication, the patient’s condition